View Author
patient hepatitis amantadine hepatitis c treatment load decrease response study therapy ribavirin group genotype virus fi rst phase hcv mono-infected patients interferon decrease placebo hcv /hiv patients analysis hepatitis c virus mono-infected baseline difference slope phase hepatology genotype 1 signi fi rst-phase netherland hcv rna kinetic effect rst-phase svr rates table hepatitis c patients placebo groups liver infection responder hepatol bene ficial effects virologic response hcv mono-infected signi ficantly peg-interferon hcv-rna hepatitis c mono-infected virologic disease trial utrecht rvr patients intention-to-treat analysis week 12 ficiency peginterferon combination gastroenterology peginterferon-alfa plasma ficant non-rvr amantadine hydrochloride interferon alfa -2b virological response non-rvr patients randomized immunode ficiency virus week 24 data analysis second-phase slope hiv /hcv patients assay factor drug users per-protocol analysis van soest
2 Most Recent Publications
|
No beneficial effects of amantadine in treatment of chronic hepatitis C patients
(Article)
Soest, H. van Schaar, P.J. van der Sluys Veer, A. van der Siersema, P.D. Schipper, M.E.I. Erpecum, K.J. van Boland , G.J. Koek, G.H. Vries, R.A. de Ooteghem, N.A. Hoek, B. van Drenth, J.P.H. Vrolijk, J.M. Lieverse, R.J. Houben, P. |
2010-07-01
|
|
Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCVHIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2aribavirin therapy
(Article)
Arends, J.E. Stuart, J.C. Baak, L.C. Ende, M.E. van der Erpecum, K.J. van Simons, C.P.M. Boland , G.J. Baarle, D. van Hoepelman, I.M. |
2009-12-01
|
